Deirdre P. Connelly
Deirdre P. Connelly's purchase track record
Deirdre P. Connelly has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/18/2022 | LNC | $112K | -9.1% | -42.4% | +5.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Lincoln Financial Closes $6.3B Talcott Reinsurance Deal. Lincoln Financial Group completed a $6.3 billion reinsurance transaction with Talcott, a significant move to manage risk and optimize capital. This deal occurs as the company prepares to report its third-quarter results on November 5. The stock is currently trading near its 52-week low, reflecting broader market caution despite the company's high dividend yield.
Transaction History
| SRPT | ▲ Buy | Grant | 16,875 | — | 6/4/2026 | View on chart |
| SRPT | ▲ Buy | Grant | 2,383 | — | 3/10/2025 | View on chart |
| SRPT | ▲ Buy | Grant | 2,842 | $0 | 9/12/2024 | View on chart |
| LNC | ▲ Buy | Open Market | 3,000 | $112K | 11/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Sarepta settles patent dispute with REGENXBIO for $39M
Sarepta Therapeutics has resolved all ongoing patent litigation with REGENXBIO through a $39 million settlement. The agreement includes a clause where REGENXBIO agrees not to sue Sarepta over existing Elevidys or AAVrh74-based capsids. This development removes a significant legal uncertainty surrounding the company's key product, allowing Sarepta to focus on presenting new neuromuscular data at an upcoming scientific meeting.
Sarepta settles patent dispute with REGENXBIO for $39M. Sarepta Therapeutics has resolved all ongoing patent litigation with REGENXBIO through a $39 million settlement. The agreement includes a clause where REGENXBIO agrees not to sue Sarepta over existing Elevidys or AAVrh74-based capsids. This development removes a significant legal uncertainty surrounding the company's key product, allowing Sarepta to focus on presenting new neuromuscular data at an upcoming scientific meeting.